Capital Cell obtains the license from the CNMV to operate in the European market
This authorization will allow Capital Cell to start operating immediately in France, Germany, Italy, Portugal, the Netherlands, Belgium and Denmark, as well as opening up the possibility of entering the rest of the European Union markets more easily
Capital Cell, an investment company specialized in biotechnology and health, has received authorization from the CNMV (the Spanish Securities & Exchange Commission) to operate under the European law ECSP 2020/1503. This authorization will allow Capital Cell to start operating immediately in France, Germany, Italy, Portugal, the Netherlands, Belgium and Denmark, as well as opening up the possibility of entering the rest of the European Union markets more easily.
Daniel Oliver, director of Capital Cell, has declared, “We firmly believe that the Capital Cell model, which has had a great positive impact on the Spanish biotech startup ecosystem, will prove just as valuable in other European ecosystems. We are working to build a platform with a European reach, and this authorization opens the way for exponential growth.”
A successful model to boost investment in biotechnology
Capital Cell has the first equity crowdfunding platform in Europe specialized in biomedicine/biotechnology and health. Between 2015 and 2023 Capital Cell has transacted more than 80 million euros for 87 companies, and is one of the most active investors in biomedical innovation in Spain.
In 2022 Capital Cell successfully closed 17 rounds with a total of 16 million euros raised in projects as relevant as Exheus, Cuideo, HCS Pharma or Arjuna Therapeutics. This year has started high with a record first quarter, with €7.5M in projects such as Oncostellae or Tensor Medical.
These figures have made Capital Cell one of the largest investors in biotechnology in Spain.